Iterum Therapeutics Faces Delisting Concerns

TL;DR

Iterum Therapeutics might get delisted, check their listing status ASAP.

AI Summary

Iterum Therapeutics plc filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on August 25, 2025. The company is incorporated in Ireland and its principal executive offices are located in Dublin.

Why It Matters

This filing indicates potential issues with Iterum Therapeutics' continued listing on an exchange, which could significantly impact its stock value and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock and operations.

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• August 25, 2025 (date) — Earliest event reported
• August 28, 2025 (date) — Date of report
• Ireland (location) — State of incorporation
• Dublin (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar
• $1.00 — Company maintain a minimum bid price of $1.00 per share (the "Bid Price Rule") for co

Filing Documents

• itrm-20250825.htm (8-K) — 42KB
• 0000950170-25-111974.txt ( ) — 143KB
• itrm-20250825.xsd (EX-101.SCH) — 24KB
• itrm-20250825_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 25, 2025, Iterum Therapeutics plc (the "Company") received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") indicating that, based on the closing bid price for the last 30 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company maintain a minimum bid price of $1.00 per share (the "Bid Price Rule") for continued listing on The Nasdaq Capital Market. The Notice does not result in the immediate delisting of the Company's ordinary shares from The Nasdaq Capital Market. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until February 23, 2026, to regain compliance with the Bid Price Rule. To regain compliance during this 180-day compliance period, the closing bid price of the Company's ordinary shares must be at least $1.00 for a minimum of 10 consecutive business days. In the event that the Company does not regain compliance with the Bid Price Rule prior to the expiration of the 180-day compliance period, the Company may be eligible for an additional 180-day compliance period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse share split, if necessary. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is not otherwise eligible, Nasdaq will provide notice that the Company's ordinary shares are to be subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: August 28, 2025 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR